This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About SpringWorks Therapeutics Stock (NASDAQ:SWTX) 30 days 90 days 365 days Advanced Chart Get SWTX alerts:Sign Up Key Stats Today's Range$46.99▼$46.9950-Day Range$46.46▼$46.9952-Week Range$28.21▼$62.00VolumeN/AAverage Volume2.66 million shsMarket Capitalization$3.54 billionP/E RatioN/ADividend YieldN/APrice Target$52.57Consensus RatingHold Company Overview SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. Read More SpringWorks Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreSWTX MarketRank™: SpringWorks Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 901st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingSpringWorks Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about SpringWorks Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SWTX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for SWTX. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for SpringWorks Therapeutics this week, compared to 6 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.83% of the stock of SpringWorks Therapeutics is held by insiders.Read more about SpringWorks Therapeutics' insider trading history. Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTX Stock News HeadlinesSpringWorks Therapeutics (SWTX) Projected to Post Quarterly Earnings on WednesdayAugust 5 at 3:53 AM | americanbankingnews.comEuropean Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 PatientsJuly 18, 2025 | quiverquant.comQYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…August 7 at 2:00 AM | Crypto 101 Media (Ad)SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform NeurofibromasJuly 18, 2025 | quiverquant.comQEuropean Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNJuly 18, 2025 | globenewswire.comEuropean Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNJuly 18, 2025 | globenewswire.comSpringWorks Therapeutics Completes Merger and DelistingJuly 1, 2025 | tipranks.comSpringWorks Therapeutics Inc (SWTX) - Investing.comJune 28, 2025 | investing.comSee More Headlines SWTX Stock Analysis - Frequently Asked Questions How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics (NASDAQ:SWTX) issued its quarterly earnings data on Friday, May, 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.30. The company had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. SpringWorks Therapeutics had a negative net margin of 115.60% and a negative trailing twelve-month return on equity of 51.10%. Does SpringWorks Therapeutics have any subsidiaries? SpringWorks Therapeutics subsidiaries include these companies: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc.. When did SpringWorks Therapeutics IPO? SpringWorks Therapeutics (SWTX) raised $126 million in an IPO on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? Top institutional investors of SpringWorks Therapeutics include Alpine Associates Management Inc. (1.52%), KRYGER CAPITAL Ltd (1.02%), Syquant Capital Sas (0.33%) and Credit Industriel ET Commercial (0.32%). Insiders that own company stock include Orbimed Advisors Llc, Saqib Islam, Badreddin Edris, Daniel Lynch, Bhavesh Ashar, Daniel Pichl and Julie Hambleton. View institutional ownership trends. What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/09/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SWTX CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees230Year Founded2017Price Target and Rating Average Price Target for SpringWorks Therapeutics$52.57 High Price Target$68.00 Low Price Target$47.00 Potential Upside/Downside+11.9%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$258.13 million Net Margins-115.60% Pretax Margin-115.60% Return on Equity-51.10% Return on Assets-43.80% Debt Debt-to-Equity RatioN/A Current Ratio4.33 Quick Ratio4.18 Sales & Book Value Annual Sales$191.59 million Price / Sales18.48 Cash FlowN/A Price / Cash FlowN/A Book Value$6.47 per share Price / Book7.26Miscellaneous Outstanding Shares75,350,000Free Float69,449,000Market Cap$3.54 billion OptionableOptionable Beta0.68 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:SWTX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.